Latest Financial Position News

Page 486 of 513
Argenica Therapeutics has dosed 80% of patients in its Phase 2 stroke trial and gained FDA orphan drug designations for its second candidate, ARG-006. The company reports a cash-positive quarter with $15 million in reserves.
Ada Torres
Ada Torres
30 Jan 2025
Syrah Resources faced operational setbacks at its Balama graphite mine due to protests, prompting a force majeure declaration, yet it maintains a robust cash position and advances its downstream Vidalia anode material facility amid growing market demand.
Maxwell Dee
Maxwell Dee
30 Jan 2025
NEXION Group reported a robust 30% increase in cash receipts for Q2 FY25, driven by strong sales growth and new satellite sector contracts. The company is actively expanding its footprint in Southeast Asia while funding ongoing M&A activities through convertible notes.
Sophie Babbage
Sophie Babbage
30 Jan 2025
Resource Mining Corporation reports promising copper-gold exploration results at its Mpanda project in Tanzania, secures $1 million in loan funding, and gains an option to acquire a 70% stake in a Saudi Arabia joint venture.
Maxwell Dee
Maxwell Dee
30 Jan 2025
Syrah Resources faces significant operational disruption at its Balama graphite mine due to ongoing protests, declaring force majeure while advancing its US-based Vidalia facility amid strong EV market growth.
Maxwell Dee
Maxwell Dee
30 Jan 2025
Aurum Resources has reported exceptional high-grade gold intercepts at its Boundiali Gold Project in Côte d'Ivoire, including a standout 1m at 150.50 g/t Au. The company is embarking on an ambitious 100,000m drilling campaign in 2025 to expand its resource base beyond the current 1.59Moz.
Maxwell Dee
Maxwell Dee
30 Jan 2025
Tesoro Gold reports its highest-ever gold assay at the Ternera Deposit alongside a strategic dual listing on the Frankfurt Stock Exchange and a strong cash position.
Maxwell Dee
Maxwell Dee
30 Jan 2025
IGO's December quarter report reveals robust performance at Greenbushes lithium mine but significant setbacks at Kwinana and Nova, culminating in a $79 million EBITDA loss and a strategic halt on Kwinana’s Plant 2.
Maxwell Dee
Maxwell Dee
30 Jan 2025
NeuroScientific Biopharmaceuticals has initiated critical IND-enabling studies for its glaucoma drug candidate EmtinB, backed by a solid cash position of A$4.5 million as of December 2024. Preliminary melanin binding results are shaping the path toward first-in-human trials.
Victor Sage
Victor Sage
30 Jan 2025
Strickland Metals has reported exceptional drilling results from its Rogozna Project in Serbia and Yandal Project in Western Australia, alongside a robust financial footing to support ongoing exploration.
Maxwell Dee
Maxwell Dee
30 Jan 2025
Lanthanein Resources has completed initial drilling phases at its Lady Grey Project and secured a six-month extension on its farm-in agreement, positioning the company for a critical assessment of its gold exploration prospects.
Maxwell Dee
Maxwell Dee
30 Jan 2025
Titan Minerals reports standout drilling results at its Dynasty Gold Project’s Iguana prospect, confirming resource growth potential with significant gold and silver intercepts. The company is advancing its 10,000m drilling campaign backed by a strong balance sheet.
Maxwell Dee
Maxwell Dee
30 Jan 2025